Immunopatological complications of anti-TNF-α biological treatment
Karin Malíčková Orcid.org 1,2
+ Affiliation
Summary
Biological treatment with therapeutic monoclonal antibodies against TNF-α is very effective and safe, and its side effects are usually mild and easily treatable. However, it may sometimes be associated with severe acute and chronic side effects, resulting from secondary immunopathologie induced by TNF-α blockade. Among the most frequent are eyrly and delayed hypersensitivity ractions to therapeutic immunoglobulin and reactions associated with the induced imbalance of the immune system. Consequences of a cytokine imbalance or antigenic cross-reactivity are significatnly rarer. This paper provides an overview and classification of immunopathological complications of anti-TNF-α blockers.
Keywords
TNF-alfa, adalimumab, inflammatory bowel disease, infliximabTo read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Bortlík M, Ďuricová D, Kohout P et al. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů: 2. vydání. Gastroent Hepatol 2012; 66 (1): 12– 22.
2. Sandborn WJ. Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol 2003; 17(1):
105– 117.
3. Tilg H, Moschen A, Kaser A. Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel
diseases. Expert Opin Biol Ther 2007; 7(7): 1051– 1059.
4. Zbořil V. Infliximab v klinické léčebné praxi. Klin Farmakol Farm 2005; 19: 67– 71.
5. Danese S. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig Liver Dis 2008; 40 (Suppl 2): S225– S228. doi: 10.1016/ S1590-8658(08)60530-7.
6. Pichler WJ. Adverse side-effects to biological agents. Allergy 2006; 61(8): 912– 920.
7. Descotes J. Immunotoxicity of monoclonal antibodies. MAbs 2009; 1(2): 104– 111.
8. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels
in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013; 108(1): 40– 47. doi:
10.1038/ ajg.2012.363.
9. Fiorino G, Danese S, Pariente B et al. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev 2014; 13(1): 15– 19. doi: 10.1016/ j.autrev.2013.06.005.
10. Visvanathan S, Marini JC, Smolen JS et al. Changes in biomarkers of inflammation and bone turnover and associations
With clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J Rheumatol 2007; 34(7): 1465– 1474.
11. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2(7): 542– 553.
12. D’Haens GR, Panaccione R, Higgins PD et al. The London position statement of the World congress of Gastroenterology on biological therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to sed by interferon-γ-expressing Th1 cells and IL-17A/ IL-22-expressing Th17 cells and respond to anti-IL-12/ IL-23 antibody treatment. Gut 2014; 63(4): 567– 577. doi: 10.1136/ gutjnl-2012-302853.
23. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol 2012; 9(9): 496– 503. doi: 10.1038/ nrgastro.2012.125.
24. Klein G, Klein E. Surveillance against tumors – is it mainly immunological? Immunol Lett 2005; 100(1): 29– 33.
25. Lawrence T. Macrophages and NF-κB in cancer. Curr Top Microbiol Immunol 2011;349: 171– 184. doi: 10.1007/ 82_2010_100.
26. Bickston SJ, Lichtenstein GR, Arseneau KO et al. The relationship between infliximab treatment and lymphoma in Crohn’s disease. Gastroenterology 1999; 117(6): 1433– 1437.
27. Peyrin-Biroulet L, Deltenre P, de Suray N et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6(6):
644– 653. doi: 10.1016/ j.cgh.2008.03.014.
28. Siegel CA, Marden SM, Persing SM et al. Risk of lymphoma associated with combination anti-tumor necrosis factor
and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7(8): 874– 881. doi: 10.1016/ j.cgh.2009.01.004.
29. Deepak P, Sifuentes H, Sherid M et al. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013;
108(1): 99– 105. doi: 10.1038/ ajg.2012.334.
30. Beigel F, Steinborn A, Schnitzler F et al. Risk of malignancies in patients with inflammatory
bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf 2014; 23(7):
735– 744. doi: 10.1002/ pds.3621.
31. Dulai PS, Thompson KD, Blunt HB et al.Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol
2014; 12(9): 1443– 1451. doi: 10.1016/ j.cgh.2014.01.021.
32. Potter C, Cordell HJ, Barton A et al. Association between anti-tumour necrosis factor treatment response and
genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis 2010; 69(7): 1315– 1320. doi:
10.1136/ ard.2009.117309.
33. Tak PP. Role of tumor necrosis factor (TNF) in immune-mediated inflammatory diseases. [online]. Available from: www.medscape.org/ viewarticle/ 545412.